These results together strongly suggest that the immunization with non-replicable MC38 CRC cells plus 40 μg of rGRA6Nt adjuvant efficiently activates both cytotoxic activity and IFN-γ production of CD8+ T cells, whereas this immunization activates only IFN-γ production of CD4+ T cells. The gene discussed is CD8A; the disease is colorectal carcinoma.